ABSTRACT Aim: This study examined whether prenatal phthalate exposure was associated with lower or upper airway inflammation in infants.
INTRODUCTION
Phthalates are synthetic chemicals that are widely used in consumer products, such as personal care products, flooring, packaging film, adhesives and toys. They are not chemically bound to these products and may leach into the surrounding environment. Consequently, they are routinely found in indoor air and dust, as well as in food and water (1) . Metabolites of phthalate compounds are also routinely found in humans (1) .
A limited number of studies are available on phthalates and they have presented epidemiological evidence linking the association between phthalate exposure and childhood asthma. Ku et al. (2) found that the presence of the monobenzyl phthalate (MBzP) metabolite in prenatal urine was associated with asthma in boys at five years of age. In addition, MBzP concentrations maternal urine has been associated with an increased occurrence of wheezing in Abbreviations BBzP, Butyl-benzyl phthalate; DPHP, Di-2-propylheptyl phthalate; DEP, Di-ethyl phthalate; DEHP, Di-ethyl-hexyl phthalate; DiDP, Di-iso-decyl phthalate; DiNP, Di-iso-nonyl phthalate; DiNCH, Di-iso-nonyl-cyclohexane-di-carboxylate; DnBP, Di-nbutyl phthalate; MBzP, Mono-benzyl phthalate; MCiNP, Monocarboxy-iso-nonyl phthalate; MCiOP, Mono-carboxy-iso-octyl phthalate; MCMHP, Mono-carboxy-methyl-hexyl phthalate; MEP, Mono-ethyl phthalate; MECPP, Mono-ethyl-carboxy-pentyl phthalate; MEHP, Mono-ethyl-hexyl phthalate; MEHHP, Mono-ethyl-hydroxy-hexyl phthalate; MEOHP, Mono-ethyloxo-hexyl phthalate; MHiDP, Mono-hydroxy-iso-decyl phthalate; MHiNP, Mono-hydroxy-iso-nonyl phthalate; MnBP, Mono-n-butyl phthalate; MOiNCH, Mono-oxo-iso-nonyl cyclohexanecarboxylic acid; MOiNP, Mono-oxo-iso-nonyl phthalate; SELMA Study, Swedish Environmental Longitudinal, Mother and child, Asthma and allergy study.
Key notes
This study examined whether prenatal phthalate exposures were associated with lower or upper airway inflammation in infancy. Our analysis suggested that exposure to BBzP and DEHP phthalates was associated with croup in infants until 12 months of age. There was no clear indication regarding any associations between prenatal phthalate exposures and wheezing or otitis media in the children during the first year of life.
boys at eight years of age. Gascon et al. (3) reported that the relative risk of wheezing, chest infections and bronchitis were significantly associated with prenatal di-ethyl-hexyl phthalate (DEHP) and MBzP metabolites at any age during the study period, which covered infants aged six to 14 months and children aged four to seven years. However, bronchitis was not examined at seven years of age. The risk of asthma at the age of seven was also increased by increasing prenatal DEHP and MBzP exposure. Whyatt et al. (4) also found associations between prenatal phthalate exposures and childhood airway issues. The risk of current asthma was more than 70% higher among children at five to 11 years of age with prenatal butyl-benzyl phthalate (BBzP) and di-n-butyl phthalate (DnBP) metabolite concentrations in the third tertile when compared with the first tertile.
However, asthma is difficult to diagnose in early life, as specific tests are limited and the diagnosis is mainly based on nonspecific signs and symptoms. Furthermore, during infancy, the prediction of future asthma disease is even more difficult. Despite this, respiratory tract inflammatory responses are a major disease burden during infancy. Assessments of environmental exposures should, therefore, be extended from relationships with just asthma to also include other clinical airway related outcomes in early life. Wheeze is one such recognisable clinical symptom. Other inflammatory morbidities and early-life conditions providing relevant proxies of significant airway inflammatory response may include viral croup and otitis media, which are upper respiratory tract infections (5-7). These inflammatory related symptoms or disorders have also been associated with the development of asthma later in life (8) . Croup is an inflammatory response to viral infections and the parainfluenza virus is the aetiology in up to 75% of croup patients (9) . It is recognised by an acute onset of breathing difficulties, a characteristic hoarse and barking cough and inspiratory stridor due to subglottic oedema. It is most likely to affect children between six months and three years of age and is more common in boys (10) .
Consequently, the aim of the current study was to examine whether prenatal levels of phthalate metabolites in the mothers' urine were related to lower or upper airway inflammatory responses to infection in infancy, defined as maternal reports of croup, wheeze or otitis media during the child's first year of life.
METHODS

Description of study population
The Swedish Environmental Longitudinal, Mother and child, Asthma and allergy study (SELMA), is a prospective longitudinal population-based pregnancy cohort study in V€ armland, Sweden. The study invited 6658 women to participate in the study during their first visit to the public antenatal care centre at around week 10 of their pregnancy. Of these, 2582 (39%) women agreed to participate. The detailed recruitment selection criteria and sample collection procedure was previously discussed by Bornehag et al. (11) .
Questionnaires
Data results from self-administered questionnaires, which include the International Study of Asthma and Allergies in Childhood (ISAAC) core health questions, were used. These were collected at two different time points: firstly when the women enroled in the SELMA study, at a median of 10 weeks of pregnancy, and secondly when their child was 12 months of age. Details of each questionnaire have previously been reported (11) . The information retrieved for this study was maternal age at delivery, asthma in the family, maternal asthma, maternal education and maternal reports about any episode of wheeze, croup and otitis media in children until 12 months of age. Croup was defined as breathing difficulties with a barking cough.
Prenatal urine samples SELMA subjects were recruited at gestational ages ranging from four to 27 weeks, with a median gestational age of 10 weeks, and 96% of the women were enroled during their first trimester.
Early pregnancy morning void urine samples were collected at enrolment. Glass containers were supplied so that the women could use them at home and the samples were transferred straight into polypropylene tubes for easy transportation. Urine samples were stored at -20°C before being processed in the laboratory at Lund University, Sweden, for analysis of phthalate metabolites (12) . Blood was collected at enrolment and stored at À70°C before being sent to the laboratory for analysis of cotinine in the serum.
Analysis of phthalate metabolites in urine
The samples were analysed by liquid chromatographytandem mass spectrometry (LC-MS/MS) as previously described (11) . The phthalate and alternative phthalate metabolites that were assessed were as follows: mono-ethyl phthalate (MEP), mono-n-butyl phthalate (MnBP), MBzP, mono-ethyl-hexyl phthalate (MEHP), mono-ethyl-hydroxyl-hexyl phthalate (MEHHP), mono-ethyl-oxo-hexyl phthalate (MEOHP), mono-ethyl-carboxy-pentyl phthalate (MECPP), mono-carboxy-methyl-hexyl phthalate (MCMHP), mono-hydroxy-iso-nonyl phthalate (MHiNP), mono-oxoiso-nonyl phthalate (MOiNP), mono-carboxy-iso-octyl phthalate (MCiOP), mono-hydroxy-iso-decyl phthalate (MHiDP), mono-carboxy-iso-nonyl phthalate (MCiNP) and mono-oxo-iso-nonyl cyclohexanecarboxylic acid (MOiNCH) (12) . Briefly, aliquots of 0.2 mL of urine were mixed with 0.1 mL of ammonium acetate (1 mol/L, pH 6.5) and 0.01 mL b-glucoronidase (Escherichia coli) and thereafter incubated at 37°C for 30 minutes. Then 0.05 mL of a 50:50 (v:v) water and acetonitrile solution of labelled ( 3 H or 13 C) internal standards of all analysed compounds were added and the samples were analysed by LC-MS/MS without any further cleanup. The creatinine concentrations were analysed according to an enzymatic method described by Mazzachi, Peake and Ehrhardt (13). Our laboratory was not able to separate the two di-iso-decyl phthalate (DIDP) and di-2-propylheptyl phthalate (DPHP) metabolites as they have the same retention time and display very similar behaviour on the mass spectrometer (14) .
Analysis of cotinine in prenatal serum as a marker for smoking Serum samples were collected at enrolment and analysed for cotinine as a biomarker for exposure to tobacco or nicotine. A detailed description of the method was previously presented in Lindh et al. (15) . Briefly, aliquots of 100 lL serum were added with labelled internal standard and, proteins were precipitated by acetonitrile and analysed using LC/MS/MS. Subjects were categorised as nonsmokers if their cotinine levels were below 0.2 ng/mL and as active smokers if their cotinine levels were greater than 15 ng/mL. If their levels were in between, subjects were considered to be passive smokers.
Statistical analyses
Urinary levels of phthalate metabolites were log (10) transformed to normalise distributions and geometric means (GMs) with 95% confidence intervals (95% CIs) were calculated. We conducted bivariate analyses to identify variables that were associated with the exposure or the outcome, namely the identification of potential confounders, using the Pearson correlation and t-test. Covariates were selected if they had significant correlations with two or more urinary phthalate metabolite concentrations. The final logistic regression models were adjusted for the mother's characteristics -age, education and smoking -as well as factors known to be associated with airway health outcomes -sex of the child, asthma and allergies in the family -and categories of creatinine in urine. Any associations between prenatal phthalate exposure and health outcomes were estimated with logistic regression and expressed as crude and adjusted odds ratio (ORs) with 95% CIs. The analysis was conducted using PROC LOGISTIC in SAS version 9.3 (SAS Institute Inc, Cary, North Carolina, USA).
This study was approved by the Regional Ethical Board in Uppsala, Sweden. Individual informed consent was obtained before each subject began participation in the study.
RESULTS
The study population consisted of 1062 mother-child pairs with complete study data. The maternal data comprised information on prenatal phthalate and phthalate alternatives, namely di-iso-nonyl-cyclohexane-di-carboxylate (DiNCH), and urine levels indicating exposure to creatinine-adjusted phthalate and phthalate alternative metabolites. The infant data covered health outcomes, namely croup, wheezing and otitis during the first year of life, and potential confounders as described in Table 1 . The median age of the mothers in the study population was 31.3 years and 56.6% of the families had a history of asthma or allergies. Based on the levels of cotinine in the prenatal serum, 5.2% of the mothers were categorised as active smokers and 5.7% were passive smokers. Just under twothirds (65.4%) of these SELMA mothers had a university degree.
To examine the risk for selection bias, we compared the study population with the entire SELMA population and found that there were no significant differences in the factors described in Table 1 , except for mother smoking status at enrolment based on their cotinine level. We found that the prevalence of active smoking was slightly lower in the study population than the entire population (data not shown).
All the measured metabolites were above the detection limit in most of the samples (98.8%), as shown in Table 2 . Urinary MnBP and MEP phthalate metabolite had the highest geometric mean concentration. The four secondary DEHP metabolites -MEHHP (17.1 ng/mL), MEOHP (16.5 ng/mL), MECPP (11.6 ng/mL) and MCMHP (6.7 ng/mL) -were more than three times higher than the urinary MEHP metabolite (3.9 ng/mL). To control for the selection bias in the SELMA study, the urinary phthalate metabolite concentrations of the study subjects were also compared with all of the SELMA subjects and no significant differences identified (Table 2) . One metabolite of the phthalate alternative DiNCH (MOiNCH) was detectable in 98.8% of all study samples, with a geometric mean concentration of 0.28 ng/mL. Croup Approximately, 9.5% of the SELMA children were reported to have suffered from croup during their first 12 months of age, with higher reported levels in boys (11.8%) than girls (7.0%), as described in Table 1 . In the crude analyses, increased prenatal BBzP and DEHP metabolite concentrations were significantly associated to maternal reports of croup until 12 months of age with an odds ratio (OR) of 1.87-1.96 and these associations were significant for boys (data not shown). About the same level of significant associations between prenatal urinary BBzP and DEHP metabolite concentration and croup in children were found when the logistic regressions were adjusted for potential confounders (Fig. 1) . Prenatal exposure to BBzP and DEHP were significantly associated with croup in boys, with no significant association with girls.
Regarding prenatal exposure for di-ethyl phthalate (DEP), DnBP, di-iso-nonyl phthalate (DiNP), DPHP, DiDP or DiNCH metabolites, there were no associations with croup up to 12 months of age.
The associations between prenatal exposure for BBzP and DEHP metabolites and croup were also seen when the phthalate metabolites concentration was categorised in quartiles, suggesting a dose-response relationship (Table 3) . The BBzP and DEHP metabolites concentrations in the fourth quartiles were all significantly associated with an increased risk of having croup when compared with the first Figure 1 Association between 1st trimester urinary levels of phthalate metabolites (10-log transformed urinary concentration) and parental reports of croup in 1062 infants during the first year of life, expressed as adjusted odds ratio (with 95% confidence interval) and stratified for sex.
1 Adjusted for sex, mother's education, mother's age, asthma in the family, smoking and creatinine in urine.
quartile. When metabolites concentration increased from the first quartile to the fourth quartile, the odds of having parental reported croup increased by 83% to 159% for different phthalate metabolites (Table 3) . These associations were mainly seen in boys.
Wheeze Approximately 30% of the SELMA children had suffered from wheezing up to 12 months of age and boys (35.4%) had more wheezing than girls (23.2%), as described in Table 1 .
The level of DiNP phthalate metabolite (MHiNP) in prenatal urine was significantly associated with wheezing in the children in the crude analyses (data not shown). When the logistic regression was adjusted for potential confounders, the same associations were found, but in this case, the association was mainly seen in girls (Fig. 2) . When the exposure was categorised into quartiles, significant associations to wheeze could be found. However, there was no clear dose-response relationship (Table 4) . No associations could be found for the other phthalate metabolites.
Otitis media
The overall prevalence of otitis media was 15.4% (Table 1) . No significant associations could be found between prenatal phthalate exposure and otitis media in the children during their first year of life, nor in crude or in adjusted analyses (data not shown).
DISCUSSION
Our findings of a relation between early pregnancy maternal levels of phthalates -DEHP and BBzP metabolitesand the incidence of infant croup indicate that such prenatal exposure could have been be a risk factor for altered airway inflammatory responses to infection in the women's offspring. Studies showing an association between early life infections or inflammatory responses, including croup, and asthma later in childhood (5, 6) highlight the importance of the present findings from a lifetime perspective. In a review that included three case-control, one prospective and one cross-sectional study, the relationship between phthalates and respiratory outcomes in children were examined. This review suggested that childhood exposure to DEHP and BBzP might increase the risk of asthma, but the average age of these children was more than one year old (16) . However, the biological mechanisms behind such an association have not been completely identified, even if there has been limited evidence from experimental studies in animal models (17) . In mice, DEHP has been linked to immunoglobulin E and G1 production (18) . Another similar study in mice over a period of 12 weeks showed that MEHP exposure induced an increase in immunoglobulin E levels (19) . More mechanistic studies are required in humans to evaluate any possible developmental immunotoxic effects of phthalate exposure and effects at later stages of life. However, but the limited data that are available point to possible multiple effects both on the innate (inflammation) and specific (adjuvancy and atopy) immune systems. Thus early life exposure to defined phthalates may be included among other environmental factors, with developmental immunotoxic effects altering the susceptibility to developing immune and inflammation-related conditions, as reviewed by Dietert (20) .
In our study, the associations between prenatal BBzP and DEHP metabolites and croup were only found for boys. Epidemiological studies have shown striking differences between the sexes with regard to children's airway problems, such as asthma, wheeze and croup, with boys suffering more frequently from these conditions than girls (2,21). Ku et al. (2) also showed stronger associations between phthalate exposure and asthma in boys than girls. The reason behind the strong association for boys remains unknown and more experimental data is needed to identify its biological mechanism.
With regarding to the associations between prenatal phthalate exposure and wheeze, our study found a significant association for one DiNP metabolite (MHiNP). However, when we analysed the exposure in quartiles (Table 4) , there were no clear indications for a doseresponse relationship and we could not find any significant associations for the other two DiNP metabolites. One study from Norway reported similar findings when they found an association between prenatal MCiOP, which is another DiNP metabolite, and the development of asthma in children (22) .
The prevalence of croup (9.5%) up to 12 months of age in the current study was slightly lower than the figure of around 15% that has been reported in other studies (5, 6) . However, this difference could be due to the fact that the children in those studies were older. The prevalence of Figure 2 Association between the first trimester urinary levels of phthalate metabolites (10-log transformed urinary concentration) and parental reports of wheeze in 1062 offspring children during the first year of life. wheezing up to 12 months of age (29.6%) in the current study was also comparable to other studies on children of the same age (23, 24) . The percentage of subjects with a family history of asthma or allergy was also comparable to other studies in similar regions (25, 26) .
Respiratory symptoms in response to infection in infants, such as croup or wheeze, are nonspecific and an asthma diagnosis is also difficult to establish. The present outcome measures were chosen to cover a clinically relevant spectrum of infant airway inflammatory conditions. Our maternal reports on croup may have been more specific, as compared to wheezing, and overall they provide a more relevant acute clinical picture, as the question included breathing difficulties in addition to the typical barking cough displayed during croup, while the maternal reports of wheeze may have included a larger number of benign respiratory sound changes, for example from the nostrils. This could be one reason why we saw stronger associations to prenatal phthalate exposure for croup than compared with wheezing. In this way, we regard a report of croup as a *Adjusted for sex, mother's education, mother's age, asthma in the family, smoking and creatinine in urine. † p-value is for the association in the overall model. relevant proxy for a clinically significant airway inflammatory response in early life. We realise that our maternal reports may have differed from doctors' diagnoses and pose limitations to our study in terms of misclassification. However, it is important to remember that the present outcome measures were in many cases self-limiting illnesses, and parents may not have sought medical care. We therefore expect the maternal reports, when compared to doctors' diagnoses during clinical visits, to be less influenced by the availability of primary or emergency care or socio-economic factors.
The phthalate metabolite levels in urine from this analysis were relatively comparable to the results from several other studies in Europe and the USA (27, 28) . However, the levels of MBzP and MBP measured in the SELMA study were slightly higher, while levels of MEP and MECPP were slightly lower compared to other studies from around the same time period (29, 30) , which could be a result of different consumer patterns with regard to products that contain phthalates. Furthermore, urinary levels of phthalate metabolites may fluctuate over time due to short half-lives and the number of products that affect humans. One single measurement may, therefore, be questioned as a representative measure for exposure. To resolve this problem, we used first morning void samples, which we regarded as the baseline level for that day. In addition, we see little evidence that our findings are a result of multiple comparisons. Even though we examined 14 metabolites separately, these metabolites came from seven parent compounds (phthalates), meaning that the number of analyses was not very high. Furthermore, all the significant results were related to DEHP or BBzP metabolites and these compounds have previously been shown to be associated with airway problems in children.
We have identified the limitations to clinical relevancy, with specific reference to croup, and this means that the associations between prenatal phthalate exposure and croup during infancy identified by this study should primarily be recognised as an indication of altered earlylife airway inflammatory responses to viral infections.
CONCLUSIONS
This study found significant associations between prenatal exposure to metabolites from two phthalates -BBzP and DEHP -and croup in children during their first year of life and dose-response relationships were indicated. There were indications for sexual dimorphism, as the associations were more pronounced in boys. This is a novel finding as it indicates an alteration of the early-life airway inflammatory response. With regard to wheezing and otitis media, no major and clear associations could be found to prenatal phthalate exposure.
